Taipei, Taiwan and San Diego, April. 24, 2017 - Senhwa Biosciences, Inc. (TPEx: 6492) raised NT$1.4 billion ($45.4 million) through the sale of 8.5 million shares at NT$162 in an IPO underwritten by SinoPac Securities.
Senhwa began trading on the Taipei Exchange mainboard on April 24. Development focuses on two main drug candidates CX-4945 and CX-5461 and multiple indications. CX-5461 was chosen as the 2015 Canada Stand Up to Cancer Dream Team Drug with potential to be the next generation synthetic lethality medicine. Senhwa was the only and the first biotech company in Asia that its drug was granted SU2C Dream Team Drug.
Currently clinical trials are ongoing or planned in Australia, Canada, United States, Korea and Taiwan.
-- END --